IGNYTA, INC. (NASDAQ:RXDX) Files An 8-K Results of Operations and Financial Condition
Item2.02.
|
Results of Operations and Financial Condition |
On May 1, 2017, Ignyta, Inc. issued a press release announcing
its results of operations for the three-month period ended March
31, 2017. The full text of such press release is furnished as
Exhibit 99.1 to this report.
In accordance with General Instruction B.2. of Form 8-K, the
information in this Current Report on Form 8-K, including Exhibit 99.1,
shall not be deemed filed for purposes of Section18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act),
or otherwise subject to the liability of that section, nor shall
it be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, whether
made before or after the date hereof, except as expressly set
forth by specific reference in such filing to this Current Report
on Form 8-K.
| Item9.01. | Financial Statements and Exhibits |
(d)
Exhibits.
The following
press release is furnished as an exhibit to this Current Report
on Form 8-K to Item 2.02 and shall not be deemed to be
filed:
|
Exhibit No. |
Description |
|
| 99.1 | Press Release, dated May1, 2017. |
About IGNYTA, INC. (NASDAQ:RXDX)
Ignyta, Inc. is an oncology biotechnology company. The Company focuses on an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. Its Rx is focused on discovering, in licensing or acquiring, then developing and commercializing molecularly targeted therapies that, sequentially or in combination, are foundational for eradicating residual disease. Its Dx focuses on pairing the product candidates with biomarker-based companion diagnostics that are designed to identify, at the molecular level, the patients likely to benefit from the therapies. Its entrectinib is an orally bioavailable, small molecule tyrosine kinase inhibitor directed to the tropomyosin receptor kinase (Trk) family tyrosine kinase receptors (TrkA, TrkB and TrkC), ROS1 and anaplastic lymphoma kinase (ALK) proteins for the treatment of solid tumors. Its entrectinib is in Phase II/III of clinical development. Its taladegib is a small molecule and hedgehog or smoothened antagonist. IGNYTA, INC. (NASDAQ:RXDX) Recent Trading Information
IGNYTA, INC. (NASDAQ:RXDX) closed its last trading session down -0.40 at 8.45 with 1,250,989 shares trading hands.